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Protein kinase B (AKT) and glycogen synthase kinase-3b (GSK-3b) are major components of insulin–
AKT signaling that plays crucial roles in various types of tissue. Recent studies found that these two
kinases are modiﬁed posttranslationally by O-GlcNAcylation. Here, we demonstrate that O-GlcNAcy-
lation regulated phosphorylation/activation of AKT and GSK-3b in different manners in kidney HEK-
293FT cells, but did not affect these two kinases in hepatic HepG2 cells. In neuronal cells, O-GlcNA-
cylation regulated phosphorylation of AKT negatively, but had no effect on GSK-3b. These results
suggest protein-speciﬁc and cell type-speciﬁc regulation of AKT and GSK-3b by O-GlcNAcylation.
Therefore, studies on the roles of AKT and GSK-3b O-GlcNAcylation should be done in a tissue-
and cell type-speciﬁc manner.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Protein kinase B (AKT) and glycogen synthase kinase-3 (GSK-
3b) are two major components of the insulin–AKT signaling path-
way that plays crucial roles in diverse aspects, such as regulation
of metabolism, energy homeostasis, and cell proliferation and
death, especially in liver, muscle, kidney, and brain. When the
signaling pathway is activated, AKT is activated through its phos-
phorylation at Thr308 and Ser473, which in turn inhibits GSK-3b
through phosphorylating it at Ser9. Thus, activation of insulin–
AKT signaling executes diverse biological actions by inhibition of
GSK-3b activity.
Protein O-GlcNAcylation is a unique type of protein glycosyla-
tion that refers to the enzymatic transfer of b-N-acetylglucosa-
mine (GlcNAc) from UDP-GlcNAc donor to the hydroxyl group
of serine/threonine residues of proteins via an O-glycosidic
bond [1]. This process is catalyzed by O-linked N-acetylglucosa-
mine transferase, or O-GlcNAc transferase (OGT). O-GlcNAc onchemical Societies. Published by E
r Basic Research in Develop-
nd, NY 10314, United States.
, chengxin.gong@csi.cuny.eduproteins can also be removed with the catalysis of b-N-acetylglu-
cosaminidase, or O-GlcNAcase (OGA). Protein O-GlcNAcylation is
regulated dynamically by these two enzymes and the intracellular
concentration of UDP-GlcNAc. Many studies have demonstrated
that O-GlcNAcylation is ubiquitous in living systems and regu-
lates numerous cellular signaling and functions, including tran-
scription, translation, protein degradation, cell signaling, cell
trafﬁcking, apoptosis, and cell cycle control [2,3]. In many cases,
O-GlcNAcylation regulates protein function via modulating the
phosphorylation of the protein. All O-GlcNAcylated proteins that
have been identiﬁed so far are also phosphoproteins. In some pro-
teins, O-GlcNAcylation and phosphorylation competitively modify
the same serine/threonine residues and are thus reciprocal to
each other [2].
It was demonstrated recently that AKT and GSK-3b are modiﬁed
by O-GlcNAc [4], suggesting that O-GlcNAc may regulate insulin–
AKT signaling. Increased O-GlcNAcylation has been shown to in-
duce insulin resistance [5–7], but contradictory studies have also
been reported [8–10]. The exact role of O-GlcNAcylation in the reg-
ulation of AKT and GSK-3b remains elusive. In particular, the cell
type-speciﬁc regulation of these two kinases by O-GlcNAcylation
has not been reported.
In this study, we employed both genetic and pharmacological
approaches in various cell lines derived from kidney, liver or brain
and demonstrated that AKT and GSK-3b activation was regulated
by O-GlcNAcylation in a cell type-speciﬁc manner.lsevier B.V. All rights reserved.
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2.1. Plasmids, antibodies and reagents
Mammalian expression vector pCMV-Entry-hOGT1 was bought
from Origene Company (Rockville, MD). The primary antibodies
used in this study are listed in Table 1. Peroxidase-conjugated
anti-mouse and anti-rabbit IgG were obtained from Jackson
ImmunoResearch Laboratories (West Grove, PA). ECL Kit was from
Amersham Pharmacia (Amersham Bioscience, Piscataway, NJ).
PUGNAc was obtained from Toronto Research Chemicals (North
York, ON, Canada), and thiamet-G was from Cayman Chemical
(Ann Arbor, MI). Insulin and other reagents were bought from
Sigma–Aldrich (St. Louis, MO).
2.2. Cell culture, transfection, and RNA interference
HEK-293FT, HepG2, and N2a cells (all purchased from American
Type Culture Collection, Manassas, VA) were maintained in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (Invitrogen, Carlsbad, CA) at 37 C. Mouse
primary hippocampal neuronal cells were prepared from hippo-
campi of embryonic C57BL/6 mice (E16). Cells were plated
(50000 cells/m2) in poly-D-lysine-coated ﬂasks (BD Falcon, Frank-
lin Lakes, NJ) and cultured in Neurobasal medium containing 2%
B-27 supplement, 50 lg/ml gentamycin, and 2 mM L-glutamine
(Invitrogen). Cultures were kept at 37 C in a moist atmosphere
(5% CO2). Half of the medium was replaced by fresh medium every
3 days, and 7-day-old cultures were used in this study. The use of
mice was carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. The protocol was approved by
the Institutional Animal Care and Use Committee of the New York
State Institute for Basic Research in Developmental Disabilities. All
surgery was performed under anesthesia, and all efforts were made
to minimize suffering.
Transfectionwas performed in triplicateswith FuGENE-6 (Roche
Diagnostics, Indianapolis, IN) in 12-well plates. The cells were
transfected by using FuGENE-6 for 48 h according to the manufac-
turer’s instructions. For knock-down of OGT expression, we used
SureSilencing shRNA plasmids for human OGT (SA Bioscience,
Frederick, MD). They were designed to target CCAAGGACGATACT-
GAAAGTT (shOGT1) and AGATCTTCGAACAGCCAGAAT (shOGT2) of
the human OGT under the control of the U1 promoter and the
GFP gene. shRNAwith the sequences (CCATCGCCAAGCTGATTAAAT)
was used to be a negative control.Table 1
Primary antibodies employed in this study.
Antibody Type Speciﬁcity Pr
RL2 Mono- O-GlcNAc 1
CTD110.6 Mono- O-GlcNAc 1
Anti-OGT (TI-14) Poly- OGT 5
Anti-AKT Poly- AKT 1
Anti-AKT-pT308 Poly- AKT-pT308 3
Anti-AKT-pS473 Poly- AKT-pS473 1
Anti-GSK-3b Mono- GSK-3b 1
Anti-GSK-3b-pS9 Poly- GSK-3b-pS9 5
Anti-GSK-3a/b Poly- Anti-GSK-3a/b 1
Anti-GSK-3a/b-pS21/9 Poly- Anti-GSK-3a/b-pS21/9 5
Anti-FoxO1-pS256 Poly- FoxO1-pS256 2
Anti-FoxO1 Poly- FoxO1 5
Anti-b-Catenin-pS33/37/T41 Poly- b-Catenin-pS33/37/T41 1
Anti-b-Catenin Poly- b-Catenin 5
Anti-GAPDH Poly- GAPDH 12.3. Immunoprecipitation
Cells were washed twice with PBS, and lysedwith the lysate buf-
fer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 50 mM NaF, 1 mM
Na3VO4, 0.5% Triton-X 100, 2 mM EDTA, 5 mM AEBSF, 10 lg/ml
aprotinin, 10 lg/ml leupeptin and 10 lg/ml pepstatin). Insoluble
materials were removed by a brief centrifugation, and the superna-
tants were incubated with the indicated antibody pre-coupled onto
protein G beads at 4 C for 4 h. The beads were washed with lysate
buffer twice and then with TBS twice. The bound proteins were
eluted by boiling them in Laemmlie sample buffer. The samples
were analyzed by Western blots.
2.4. Western blots
Cultured cells in 12-well plates were lysed in 250 ll Laemmli
buffer (125 mM Tris–HCl, pH 6.8, 4% SDS, 20% glycerol, 2% b-
mercaptoethanol, and 0.005% bromophenal blue), followed by
heating in boiling water for 5 min. Protein concentrations of the
samples were determined by using a modiﬁed Lowry method
[11]. The levels of speciﬁc proteins and their phosphorylation were
determined by Western blots using 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE). The blots were
developed using ECL and then quantiﬁed densitometrically using
the Molecular Imager System (Bio-Rad, Hercules, CA).
2.5. Statistical analysis
Where appropriate, the data are presented as mean ± S.D. Data
points were compared by the unpaired two-tail student’s t test.
3. Results
3.1. AKT and GSK-3b are modiﬁed by O-GlcNAc
We ﬁrst conﬁrmed the O-GlcNAc modiﬁcation of AKT and GSK-
3b. HEK-293FT cells were ﬁrst transfected with OGT and/or treated
with thiamet-G, a selective O-GlcNAcase inhibitor, to elevate
global protein O-GlcNAcylation, followed by immunoprecipitation
of O-GlcNAcylated proteins from the cell lysate using a mixture of
two O-GlcNAc antibodies, RL2 and CTD110.6. The amounts of O-
GlcNAcylated AKT and GSK-3b were then determined by Western
blots. The RL2 blot indicated (i) that thiamet-G treatment increased
the global protein O-GlcNAcylation level slightly, whereas OGT
transfection increased it dramatically, and (ii) that the O-GlcNAcy-
lated proteins were successfully immunoprecipitated (Fig. 1A). AKTotein loaded (lg) Dilution Source/Reference
0 1:2000 Afﬁnity Bioreagents, Golden, CO, USA
0 1:2000 Covance, Emeryville, CA, USA
1:2000 Sigma–Aldrich, St. Louis, MO, USA
1:1000 Cell Signaling Technology, MA, USA
0–50 1:500 Cell Signaling Technology
0 1:1000 Cell Signaling Technology
1:1000 Cell Signaling Technology
1:1000 Cell Signaling Technology
1:1000 Cell Signaling Technology
1:1000 Cell Signaling Technology
0 1:1000 Cell Signaling Technology
1:1000 Cell Signaling Technology
0 1:1000 Cell Signaling Technology
1:1000 Cell Signaling Technology
1:2000 Santa Cruz, CA, USA
Fig. 1. Detection of O-GlcNAcylation of AKT and GSK-3b. (A) HEK-293FT cells were transfected with OGT for 36 h and then treated with 25 lM thiamet-G for 12 h. The O-
GlcNAcylated proteins were immunoprecipitated from the cell lysate using a mixture of two antibodies, RL2 and CTD110.6, and detected by Western blots developed with
RL2. (B, C) AKT (B) and GSK-3b (C) were immunoprecipitated from the lysates of HEK-293FT cells after transfection with OGT or shOGT for 48 h, and O-GlcNAcylation level
was detected by Western blots developed with RL2. As a control, a buffer instead of cell extracts was added (right lane). The AKT (B) and GSK-3b (C) blots were included to
conﬁrm the success of immunoprecipitation.
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that they are O-GlcNAcylated or co-immuno-precipitated with
other O-GlcNAcylated proteins under this condition. Increased
amounts of AKT and GSK-3b in the immunoprecipitates after
OGT transfection and thiamet-G treatment indicated that the
immuno-complex responded to elevated global level of O-GlcNA-
cylation in the cells.
To verify the O-GlcNAc modiﬁcation of AKT and GSK-3b, we
immunoprecipitated AKT and GSK-3b from the lysate of HEK-
293FT cells after transfection with OGT to elevate or with shOGT
to reduce O-GlcNAcylation and detected their O-GlcNAcylation le-
vel with RL2 antibody. We observed (i) that both AKT and GSK-3b
were modiﬁed by O-GlcNAc and (ii) that OGT expression increased
and OGT knockdown decreased the O-GlcNAcylation of AKT and
GSK-3b (Fig. 1B, C). These results further conﬁrmed marked modi-
ﬁcations of AKT and GSK-3b with O-GlcNAc.
3.2. O-GlcNAcylation regulates AKT and GSK-3b phosphorylation in
kidney HEK-293FT cells
To investigate the functional impact of O-GlcNAcylation on
AKT, we studied phosphorylation of AKT at Thr308 and Ser473,
which determine its kinase activity, in HEK-293FT cells transfected
with OGT or shOGT in combination with thiamet-G treatment. We
also treated the cells with insulin while they were cultured in nor-
mal or serum-free medium to stimulate the insulin–AKT signaling
pathway, which allowed a bigger window for investigating the ef-
fects of O-GlcNAcylation on this pathway. As expected, insulin
treatment stimulated phosphorylation of AKT at Thr308 and
Ser473 and of GSK-3b at Ser9 dramatically under both culture con-
ditions (Fig. 2). We found that OGT overexpression led to a dra-
matic elevation of O-GlcNAcylation that was accompanied by a
marked decrease in Ser473 phosphorylation of AKT under both
culture conditions and either with or without insulin stimulation
(Fig. 2). A decrease in Thr308 phosphorylation of AKT was seen
only after cells were cultured under serum-free medium and after
insulin stimulation. Thiamet-G also induced a marked increase in
O-GlcNAcylation, but it failed to induce any signiﬁcant changes of
AKT phosphorylation at either site, although an additive effect
with OGT expression was evident under basal conditions. Knock-
down of OGT did not result in any signiﬁcant change in AKT phos-
phorylation, probably due to a low level of AKT O-GlcNAcylation in
these cells without OGT over-expression. None of the OGT expres-
sion or knockdown or thiamet-G treatment affected the level of
AKT in these cells.Knockdown of OGT signiﬁcantly decreased phosphorylation of
GSK-3b at Ser9 when the cells were cultured under both media
and with or without insulin stimulation. However, neither OGT
over-expression nor thiamet-G treatment resulted in any signiﬁ-
cant changes of GSK-3b phosphorylation (Fig. 2).
To learn the functional consequences of the altered phosphory-
lation/activation of AKT and GSK-3b in response to the alterations
of O-GlcNAcylation in HEK-293FT cells, we investigated the down-
stream targets of these two kinases. AKT activation can prevent
cellular apoptosis through phosphorylation of the transcription
factor Forkhead box protein O1 (FoxO1) [12]. We found that OGT
overexpression decreased FoxO1 phosphorylation level at Serine
256 site both with and without insulin stimulation (Fig. 3). These
results are consistent with the increased O-GlcNAcylation and
decreased phosphorylation/activity of AKT with OGT overexpres-
sion (Fig. 2B,D). GSK-3b phosphorylates and regulates b-catenin’s
activity in the regulation of cell growth [13]. We found that OGT
knockdown signiﬁcantly increased phosphorylation of b-catenin
both with and without insulin stimulation (Fig. 3), which is consis-
tent with the decrease of Ser9 phosphorylation of GSK-3b and thus
increase in its kinase activity under these conditions (Fig. 2B, D).
These data suggest that the regulation of phosphorylation/activa-
tion of AKT and GSK-3b has functional consequences.
3.3. O-GlcNAcylation does not regulate AKT or GSK-3b
phosphorylation in hepatic HepG2 cells
To investigate whether O-GlcNAcylation also regulates phos-
phorylation/activation of AKT and GSK-3b in other types of cells as
inHEK-293FT cells, we ﬁrst selectedHepG2 cells (humanhepatocel-
lular carcinoma cells), because the liver is a glucose sensor and plays
an important role in regulating glucose homeostasis. We took the
same approach as used for HEK-293FT cells and observed that insu-
lin stimulation for 5–60 min increased phosphorylation of AKT and
GSK-3bmarkedly (Fig. 4A, B).We found that, unlike HEK293FT cells,
neither over-expression of OGT or shOGT nor thiamet-G treatments
led to alterations of phosphorylation or the levels of AKT and of
GSK-3b in HepG2 cells, although OGT over-expression and thia-
met-G treatment increased O-GlcNAcylation in HepG2 cells
(Fig. 4B–D). We also studied FoxO1, a downstream target of AKT,
and b-catenin, a downstream target of GSK-3b, and found no signif-
icant changeof their phosphorylationuponalterationofO-GlcNAcy-
lation (Fig. 4E–G). These results suggest that the phosphorylation/
activation of AKT andGSK-3b in liver cellsmight not be regulated by
O-GlcNAcylation.
Fig. 2. Regulation of AKT and GSK-3b phosphorylation by O-GlcNAcylation in HEK-293FT cells. (A, B) HEK-293FT cells cultured in normal or serum-free medium were
transfected with OGT or shOGT for 36 h, followed by treatment with 25 lM thiamet-G for 12 h. Then some cells were also treated with 100 nM insulin for 30 min. The levels
of OGT, O-GlcNAc, AKT, and GSK-3b and their phosphorylation were determined by Western blots developed with antibodies indicated at the right side of each blot. (C, D)
Densitometric quantiﬁcations of AKT-pT308, AKT-pS473, and GSK-3b-pS9 after normalization by the kinase levels (from ATK and GSK-3b blots, respectively). Data are
presented as mean ± S.D. ⁄ p < 0.05 vs. the mock transfection control group.
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Fig. 3. Phosphorylation of AKT and GSK-3b substrates after alteration of O-GlcNAcylation in HEK-293FT cells. (A) HEK-293FT cells cultured in serum-free medium were
transfected with OGT or shOGT for 36 h, followed by treatment with 25 lM thiamet-G for 12 h. Some cells were then also treated with 100 nM insulin for 30 min. The levels of
AKT substrate FoxO1 and GSK-3b substrate b-Catenin and their phosphorylation were determined by Western blots. (B, C) Densitometric quantiﬁcations of FoxO1-pS256 and
b-Catenin-pS33/37/T41 after normalization by the total protein levels. Data are presented as mean ± S.D. ⁄ p < 0.05 vs. the mock transfection control group.
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has no effect on GSK-3, in neuronal cells
We next investigated the regulation of phosphorylation/activa-
tion of AKT and GSK-3b by O-GlcNAc in a neuroblastoma cell line,
N2a cells, because both O-GlcNAcylation and OGT are abundant in
the brain. We found that OGT overexpression resulted in decreased
Ser473 phosphorylation of AKT, whereas OGT knockdown led to in-
creased Ser473 phosphorylation of AKT (Fig. 5A–F), suggesting a
negative regulation of AKT phosphorylation/activation by O-Glc-
NAcylation. Phosphorylation of AKT at Thr308 was not detectable
in N2a cells under any conditions we tested, probably due to a very
low phosphorylation level at this site under these conditions (data
not shown). However, phosphorylation of GSK-3a at Ser21 or GSK-
3b at Ser9, as detected by using an antibody against both GSK-3a
and GSK-3b, was not signiﬁcantly altered when O-GlcNAcylation
was either up-regulated by OGT overexpression or down-regulated
by shOGT expression. When N2a cells were treated with DON to
inhibit the intracellular synthesis of UDP-GlcNAc, we observed de-
creased O-GlcNAcylation and a concurrent increase in Ser473
phosphorylation of AKT (Fig. 5G, H), conﬁrming the negative regu-
lation of AKT phosphorylation by O-GlcNAcylation. However, whenN2a cells were treated with the O-GlcNAcase inhibitors thiamet-G
or PUGNAc to increase O-GlcNAcylation level, we also found in-
creased Ser473 phosphorylation of AKT, suggesting that these
two O-GlcNAcase inhibitors may have additional, stronger actions
that oppose the effect of increased O-GlcNAcylation on Ser473
phosphorylation of AKT.
We also studied the regulation of phosphorylation/activation of
AKT and GSK-3b by O-GlcNAc in primary mouse hippocampal neu-
ronal cells. To get a wide window to observe the regulation, we de-
pleted B-27 supplements from the standard culture medium and
added insulin to stimulate the cells in addition to the normal cul-
ture condition. As expected, depletion of B-27 down-regulated
phosphorylation of AKT and GSK-3b, whereas insulin treatment
activated the phosphorylation dramatically (Fig. 6A). In consistent
with our expectation, we found that DON and PUGNAc treatments
decreased and increased O-GlcNAcylation, respectively. Although
these treatments did not alter the phosphorylation of either AKT
or GSK-3b under basal culturing conditions, DON treatment en-
hanced insulin-induced phosphorylation of AKT at both Ser473
and Thr308 in the hippocampal neuronal cells (Fig. 6). However,
the phosphorylation of GSK-3b at Ser9 was not affected by either
DON or PUGNAc treatments. As seen in N2a cells, PUGNAc also
Fig. 4. Phosphorylation and activity of AKT and GSK-3b after alterations of O-GlcNAcylation in HepG2 cells. (A) HepG2 cells were treated with 100 nM insulin for 0, 5, 30 or
60 min, and the levels of AKT and GSK-3b and their phosphorylation were determined by Western blots. (B) HepG2 cells cultured in serum-free medium for 12 h were
transfected with OGT or shOGT for 36 h, followed by treatment with 25 lM thiamet-G for 12 h. Then some cells were also treated with 100 nM insulin for 30 min. The levels
of OGT, O-GlcNAc, AKT, and GSK-3b as well as their phosphorylation were determined by Western blots. (C, D) Densitometric quantiﬁcations of AKT-pS473 and GSK-3b-pS9
after normalization by the kinase levels (from ATK and GSK-3b blots, respectively). AKT-pT308 was not quantiﬁed because of the weak immuno signals with high
backgrounds. (E) The levels of AKT substrate FoxO1 and GSK-3b substrate b-catenin and their phosphorylation were determined by Western blots. (F, G) Densitometric
quantiﬁcations of FoxO1-pS256 and b-Catenin-pS33/37/T41 after normalization by the total protein levels. Data are presented as mean ± S.D. ⁄ p < 0.05 vs. the mock
transfection control group.
Fig. 5. Regulation of AKT but not GSK-3 by O-GlcNAcylation in N2a cells. (A–F) N2a cells were transfected with OGT (A) or shOGT (D) for 48 h, and the cell lysates were
analyzed by Western blots. Densitometric quantiﬁcations of the blots are shown on the right sides of the blots (B, C, E, F). (G) Western blots of the lysates of N2a cells after
treatment with Don, PUGNAc or thiamet-G for 12 h. (H) Densitometrical quantiﬁcations of AKT-pS473 from the panel G. Data are presented as mean ± S.D. ⁄ p < 0.05 vs. the
control group.
2448 J. Shi et al. / FEBS Letters 586 (2012) 2443–2450
Fig. 6. Regulation of AKT but not GSK-3 by O-GlcNAcylation in primary mouse hippocampal neuronal cells. Primary hippocampal neuronal cells were cultured in Neurobasal
medium supplemented with 2% B27 for seven days, followed by depletion of B27 or treatment with 50 lMDON or 100 lM PUGNAc for 12 h. Then, the cells were treated with
100 nM insulin for 30 min before being harvested. (A) Western blots of the cell lysates developed with antibodies indicated. (B) Densitometric quantiﬁcations of the blots
shown in A. Data are presented as mean ± S.D. ⁄ p < 0.05 vs. the control group.
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primary mouse hippocampal neuronal cells. These results suggest
similar regulations of AKT phosphorylation/activation by O-GlcNA-
cylation in primary mouse hippocampal neuronal cells as in N2a
cells.
4. Discussion
O-GlcNAc has been found to modify AKT [5,14] and GSK-3b [15]
in recently, suggesting that O-GlcNAc modiﬁcation may regulate
their phosphorylation/activities. In the present study, we demon-
strated that AKT and GSK-3b were regulated by O-GlcNAcylation
in a cell type-speciﬁc manner. By investigating in cell lines derived
from kidney, liver, and brain, we found that the effects of O-GlcNA-
cylation on phosphorylation/activation of AKT and GSK-3b were
verydifferent indifferent types of cells. InHEK-293FT cells thatwere
derived from human embryonic kidney cells transformed with the
SV40 large T antigen, elevated O-GlcNAcylation as the result of
OGT overexpression led to decreased phosphorylation of AKT at
Ser473 and Thr308. These results suggest that these serine and thre-
onine residues might be O-GlcNAcylated. The exact sites of AKT
O-GlcNAcylation have not yet been mapped. When OGT was
knocked down by using shOGT, we did not observe any signiﬁcant
alterations of AKT phosphorylation. This was probably due to a
relatively low level of AKT O-GlcNAcylation in these cells under
the basal condition, and thus OGT knockdown induced a much
smaller change of O-GlcNAcylation than that induced by OGT over-
expression, as shown in Fig. 2. Such a small decrease in O-GlcNAcy-
lation might be unable to cause a detectable increase in AKT
phosphorylation.
The effects of O-GlcNAcylation on Ser9 phosphorylation of GSK-
3b was apparently opposite to those on AKT phosphorylation in
HEK293-FT cells. We observed no signiﬁcant changes of GSK-3b
phosphorylation upon OGT overexpression, but a marked decrease
upon OGT knockdown. These results suggest that O-GlcNAcylationmay regulate GSK-3b Ser9 phosphorylation positively, which is
consistent with the potential role of elevated O-GlcNAcylation in
inducing insulin resistance [5–7,16]. The positive regulation of
GSK-3b Ser9 phosphorylation by O-GlcNAcylation also excludes
the possibility of GSK-3b O-GlcNAcylation at Ser9. Otherwise, a
negative and reciprocal regulation would be expected. The failure
of OGT overexpression to induce an increase in GSK-3b Ser9 phos-
phorylation probably resulted from an O-GlcNAcylation-induced
reduction of AKT phosphorylation/activation that could have op-
posed and diminished the direct effect of O-GlcNAcylation on
Ser9 phosphorylation of GSK-3b.
It is surprising to observe no signiﬁcant changes in phosphory-
lation of AKT or GSK-3b with either overexpression or knockdown
of OGT in HepG2 cells, which were derived from human hepatocel-
lular carcinoma. However, Soesanto et al. observed an increase in
AKT phosphorylation at Thr308 and Ser473 and GSK-3b phosphor-
ylation at Ser9 in HepG2 cells after adenoviral-mediated overex-
pression of OGA [17]. The apparent discrepancy might be that
the viral vector induced very high expression of OGA that had
modulated O-GlcNAcylation of AKT and GSK-3b to an extent that
was not seen in the present study.
Recent studies have suggested that insulin–AKT signaling also
regulates glucose metabolism in the brain and plays an important
role in neural development and neuronal activities and affects
learning and memory [18]. The role of brain insulin dysfunction
in AD has been reported [19,20]. AD has, in fact, been referred to
as ‘‘type 3 diabetes’’ [4,21,22]. We have recently demonstrated
a decrease in brain O-GlcNAcylation in AD and proposed its
contribution to neurodegeneration via promoting abnormal hyper-
phosphorylation of tau [23–26]. Whether and how O-GlcNAcyla-
tion regulates insulin–AKT signaling in the neuron has not been
reported. By using overexpression and knockdown/inhibition of
OGT in both N2a and primary mouse hippocampal neuronal cells,
we found in the present study a negative regulation of AKT phos-
phorylation by O-GlcNAcylation in the neuron.
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O-GlcNAcylation has been reported in several types of cells. In 3T3-
L1 adipocytes, insulin-stimulated O-GlcNAcylation of AKT inhibits
its phosphorylation at Thr308, which shuts down its kinase activity
anddown-regulates its signaling [5,16]. Inendothelial cells, theO-Glc-
NAcylation level of AKT correlates with reduced AKT activity and
phosphorylationat Ser473[27]. Inb-pancreatic cells, increasedO-Glc-
NAc anddecreased Ser473phosphorylation of AKT are observed upon
glucosamine treatments that increase O-GlcNAcylation levels [28]. In
high glucose-exposed mesangial cells following OGT shRNA expres-
sion, elevation of Thr308 and Ser473 phosphorylation of AKT is also
seen [29]. The present study shows this negative regulation of AKT
phosphorylation/activation by O-GlcNAcylation in the kidney cells
and neurons, but not in the hepatocytes.
It is interesting to note that although both OGT overexpression
and thiamet-G treatment led to a marked increase in global O-Glc-
NAcylation, thiamet-G-induced elevation of O-GlcNAcylation did
not result in any decrease in AKT phosphorylation as OGT overex-
pression did in HEK293-FT cells. Furthermore, increased global
O-GlcNAcylation due to inhibition of OGA with thiamet-G or PUG-
NAc even increased AKT phosphorylation in neuronal cells. Consis-
tent with the present study, a previous study showed that PUGNAc
treatments did not attenuate IGF-1-induced AKT phosphorylation
in neuroblastoma SH-SY5Y cells [30]. A possible underlying reason
for this is that unlike OGT overexpression, inhibition of OGA may
not lead to increased O-GlcNAcylation of AKT, although it does
for numerous other proteins. This is supported by our observation
that OGT overexpression, but not thiamet-G treatment, led to in-
creased AKT O-GlcNAcylation in HEK293-FT cells (Fig. 1A). This
possibility is consistent with a probably more regulatory role of
OGT than OGA in AKT O-GlcNAcylation, because OGT is recruited
together with AKT to the cytoplasmic membrane upon induction
of insulin signaling, where OGT has direct access to AKT and cata-
lyzes its O-GlcNAcylation [5]. The differential roles of OGT and OGA
in regulation of AKT O-GlcNAcylation might partially explain the
contradictory conclusions in the literature of whether elevated
O-GlcNAcylation promotes insulin resistance. The OGA inhibitors
might also have additional functions that activate the upstream ki-
nase activity of AKT, which in turn might lead to AKT phosphory-
lation in neuronal cells.
In conclusion, the present study demonstrates protein-speciﬁc
and cell type-speciﬁc regulation of AKT and GSK-3b by O-GlcNAcy-
lation. Considering the diverse roles of insulin–AKT signaling in
various organs and cells, we cannot assume that O-GlcNAcylation
regulates this signaling in the same fashion. The role of O-GlcNAcy-
lation in insulin resistance should be re-assessed in a tissue- and
cell type-speciﬁc manner. The role of O-GlcNAcylation in neuronal
physiology and neuroplasticity must be investigated in the neuron.
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